Chronic Obstructive Pulmonary Disease and Pulmonary Hypertension: Prevalence and Quality of Life

Chronisch Obstruktive Lungenerkrankung Und Pulmonale Hypertonie: Prävalenz Und Lebensqualität

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01423071

Enrollment

220

Registered

2011-08-25

Start date

2011-08-31

Completion date

2015-01-31

Last updated

2015-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension, Pulmonary, Pulmonary Disease, Chronic Obstructive

Keywords

Pulmonary Hypertension, Chronic obstructive pulmonary disease, Prevalence, Quality of life

Brief summary

The purpose of this study is to determine the prevalence of pulmonary hypertension (PH) among patients suffering from Chronic Obstructive Pulmonary Disease (COPD) and to assess the quality of life in those patients with concomitant PH compared to COPD patients without PH and those only suffering from pulmonary arterial hypertension (PAH) respectively.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Age ≥ 18 years * Known or newly diagnosed COPD or PAH * Written informed consent * Present long-term oxygen treatment is no exclusion criterion

Exclusion criteria

* Age \< 18 years * Right-heart catheterization not reasonable * Pregnancy, Lactation * Life expectancy \<12 months due to any diseases aside from COPD * Any medical, psychological or other condition, which limits the patient's ability to provide informed consent * No written informed consent provided * Current participation in another clinical trial

Design outcomes

Primary

Measure	Time frame	Description
Prevalence of PH	At baseline	Prevalence of PH as defined by ESC/ERS guidelines (mean pulmonary arterial pressure ≥25 mmHg, assessed by right-heart catheterization) among the subgroup of COPD GOLD III and IV patients.

Secondary

Measure	Time frame	Description
Quality of life	One year	Explorative data analysis to assess correlation between quality of life and PH, by comparison of COPD patients with and without PH and a reference group of patients with only PAH.

Countries

Germany

Outcome results